Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Sell

Wall Street Data Solutions Rating

Neutral

B

Lexaria Bioscience Corp. Common Stock (LEXX)

Pharmaceutical Preparations

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

100 - 740 MCCURDY ROAD
KELOWNA, A1

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/08/2006

Market Cap

49,770,510

Shares Outstanding

10,440,000

Weighted SO

10,435,441

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

REVB --.--%

ZURA --.--%

PHIO --.--%

ZVSA --.--%

RNAZ --.--%

IMMX --.--%

CNSP --.--%

EFTR --.--%

NAVB --.--%

Beta

1.0210

Last Div

0.0000

Range

0.844-6.85

Chg

-0.0020

Avg Vol

213735

Mkt Cap

49770510

Exch

NASDAQ

Country

CA

Phone

250 765 6424

DCF Diff

4.7403

DCF

-1.5503

Div Yield

0.0000

P/S

132.0716

EV Multiple

-9.4164

P/FV

4.3088

Div Yield %

0.0000

P/E

-8.9933

PEG

-0.4252

Payout

0.0000

Current Ratio

58.2730

Quick Ratio

58.2730

Cash Ratio

54.2082

DSO

201.8932

DIO

0.0000

Op Cycle

201.8932

DPO

1127.7905

CCC

-925.8973

Gross Margin

0.8958

Op Margin

-12.1701

Pretax Margin

-12.9260

Net Margin

-12.8697

Eff Tax Rate

-0.0051

ROA

-0.4841

ROE

-0.8280

ROCE

-0.4650

NI/EBT

0.9956

EBT/EBIT

1.0621

EBIT/Rev

-12.1701

Debt Ratio

0.0142

D/E

0.0141

LT Debt/Cap

0.0113

Total Debt/Cap

0.0139

Int Coverage

-999999.9999

CF/Debt

-32.8854

Equity Multi

0.9897

Rec Turnover

1.8079

Pay Turnover

0.3236

Inv Turnover

0.0000

FA Turnover

1.0393

Asset Turnover

0.0376

OCF/Share

-0.3384

FCF/Share

-0.3520

Cash/Share

0.6139

OCF/Sales

-12.4428

FCF/OCF

1.0400

CF Coverage

-32.8854

ST Coverage

-172.0112

CapEx Coverage

-25.0141

Div&CapEx Cov

-25.0141

P/BV

4.3088

P/B

4.3088

P/S

132.0716

P/E

-8.9933

P/FCF

-10.2062

P/OCF

-9.3018

P/CF

-9.3018

PEG

-0.4252

P/S

132.0716

EV Multiple

-9.4164

P/FV

4.3088

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 11, 08:30 Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream GlobeNewswire Inc. Jan 09, 08:30 Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform GlobeNewswire Inc. Oct 31, 08:31 Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Revenue Product Segmentation